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Research
Ambient air pollution has gained recogni-
tion as an important source of cardio  vascular 
morbidity and mortality (Brook et al. 2004; 
Dockery et al. 1993; Pope et al. 1995). In 
addition to long-term mortality, daily fluc-
tuations in fine particles [particulate mat-
ter with median aerodynamic diameter 
< 2.5 µm (PM2.5)] and ozone have been 
linked to short-term cardiovascular and pul-
monary mortality (Bell et al. 2004; Brook 
et al. 2004; Dominici et al. 2006). Studies 
in subjects with implanted cardioverter 
defibrillators demonstrating an association 
between PM2.5 elevation and increased inci-
dence of ventricular arrhythmias and rapid 
atrial fibrillation suggest autonomic dys-
regulation as a putative pathway to these 
clinical end points (Dockery et al. 2005; 
Peters et al. 2000; Rich et al. 2006). The role 
of PM2.5-mediated autonomic dysregula-
tion has been explored using heart rate vari-
ability (HRV) as a surrogate for autonomic 
tone (Task Force of the European Society 
of Cardiology 1996) in epidemiologic stud-
ies (Creason et al. 2001; Gold et al. 2000; 
Liao et al. 1999; Magari et al. 2001), animal 
studies (Godleski et al. 2000), and human 
experimental studies (Devlin et al. 2003; 
Gong et al. 2003). Yet there is still a scar-
city of knowledge about health effects of 
potential synergy between PM2.5 and ambi-
ent gaseous copollutants (National Research 
Council 2004). Of these copollutants, O3 
inter  action is of particular interest given its 
possible role in local oxidation, creation of 
free radicals, and potentiation of pollutant 
deposition onto surfaces (Finlayson-Pitts 
and Pitts 1997; Meng et al. 1997). 
To assess whether the association between 
particulate exposure and autonomic func-
tion is altered by concomitant O3, we con-
ducted a randomized, single-blind, crossover 
study, with subjects undergoing exposure 
to concentrated ambient particles (CAPs), 
O3, combined CAPs and O3, and filtered air. 
Secondary aims of the study included assess-
ing for a dose‒response relationship for CAPs 
exposure both with and without O3, assessing 
blood pressure (BP) response to exposures, 
and assessing whether a subgroup of subjects 
with asthma was more susceptible to auto-
nomic dysregulation after exposures.
Materials and Methods
Study population. The study was approved by 
the Human Subjects Review Committee of 
the University of Toronto and was performed 
at the Gage Occupational and Environmental 
Health Unit in Toronto, Ontario, Canada. 
Informed consent was obtained from 50 male 
and female nonsmoking subjects, 19‒48 years 
of age, without any history of cardiovascular 
disease or risk factors. Subjects were pooled 
from two separate studies, study A and study 
B. One subject participated in both studies.
From July 1999 through February 2003, 
study A conducted exposures on subjects with 
and without asthma (n = 21). Asthmatic status 
was determined by physician diagnosis and con-
firmed by methacholine challenge. Asthmatic 
subjects had been off of any short-acting bron-
chodilators from midnight onward and off of 
corticosteroid treatment for at least 1 month 
before all visits. Study B was conducted from 
January 2004 through October 2007, and 
included only subjects without asthma (n = 30). 
BP responses to exposure in study B have been 
reported previously (Urch et al. 2004).
Exposure protocol. All subjects were 
intended to receive four 2-hr exposures in 
random order as follows: a) sham filtered 
air (FA) with particles removed by a high-
efficiency particulate arrester (HEPA) filter 
and no added O3; b) CAPs with target PM2.5 
mass concentration of 150 µg/m3; c) O3 with 
target concentration of 120 ppb; and d) CAPs 
+ O3. In addition, a subset of participants 
in study A underwent additional exposures 
with a target CAPs mass concentration of 
60 µg/m3. Exposures within the same subject 
were separated by at least 2 weeks, and all 
Address  correspondence  to  M.A.  Mittleman, 
Cardiovascular  Epidemiology  Research  Unit, 
Cardiovascular Division, Beth Israel Deaconess 
Medical Center, 330 Brookline Ave., MASCO 4th 
Floor, Boston, MA 02215 USA. Telephone: (617) 
632-7694. Fax: (617) 632-7698. E-mail: mmittlem@
bidmc.harvard.edu
This research was supported in part by grants 
ES013804 and ES009825 from the National 
Institute of Environmental Health Sciences, National 
Institutes of Health, and R827353 and R832416 
from the U.S. Environmental Protection Agency.
The authors declare they have no competing 
  financial interests.
Received 5 January 2009; accepted 23 April 2009.
Autonomic Effects of Controlled Fine Particulate Exposure in Young Healthy 
Adults: Effect Modification by Ozone
Asghar A. Fakhri,1 Ljubomir M. Ilic,1,2 Gregory A. Wellenius,1 Bruce Urch,3,4 Frances Silverman,3,5 Diane R. Gold,6,7 
and Murray A. Mittleman1,7
1Cardiovascular Epidemiology Research Unit, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, Massachusetts, USA; 2Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA; 3Gage Occupational 
and Environmental Health Unit, St. Michael’s Hospital, Toronto, Ontario, Canada; 4Institute of Medical Science, and 5Dalla Lana School 
of Public Health and Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 6Channing Laboratory, Department 
of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; 7Department of Epidemiology, 
Harvard School of Public Health, Boston, Massachusetts, USA
Ba c k g r o u n d: Human controlled-exposure studies have assessed the impact of ambient fine 
  particulate matter on cardiac autonomic function measured by heart rate variability (HRV), but 
whether these effects are modified by concomitant ozone exposure remains unknown.
oB j e c t i v e: In this study we assessed the impact of O3 and particulate matter exposure on HRV in 
humans.
Me t h o d s : In a crossover design, 50 subjects (19‒48 years of age) were randomized to 2-hr con-
trolled exposures to filtered air (FA), concentrated ambient particles (CAPs), O3, or combined CAPs 
and ozone (CAPs + O3). The primary end point was change in HRV between the start and end of 
exposure. Secondary analyses included blood pressure (BP) responses, and effect modification by 
asthmatic status.
re s u l t s: Achieved mean CAPs and O3 exposure concentrations were 121.6 ± 48.0 µg/m3 and 
113.9 ± 6.6 ppb, respectively. In a categorical analysis, exposure had no consistent effect on HRV 
indices. However, the dose–response relationship between CAPs mass concentration and HRV 
indices seemed to vary depending on the presence of O3. This heterogeneity was statistically sig-
nificant for the low-frequency component of HRV (p = 0.02) and approached significance for the 
high-frequency component and time-domain measures of HRV. Exposure to CAPs + O3 increased 
diastolic BP by 2.0 mmHg (SE, 1.2; p = 0.02). No other statistically significant changes in BP were 
observed. Asthmatic status did not modify these effects.
co n c l u s i o n: The potentiation by O3 of CAPs effects on diastolic BP and possibly HRV is of small 
magnitude in young adults. Further studies are needed to assess potential effects in more vulnerable 
populations.
key w o r d s : asthma, blood pressure, heart rate variability, ozone, particulate matter. Environ 
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exposures were conducted at the same time of 
day to avoid confounding by circadian varia-
tions (Brook et al. 2002; Task Force of the 
European Society of Cardiology 1996). In 
addition, subjects were seated at rest in the 
exposure chamber 15 min before receiving the 
intended exposure to allow for acclimation to 
sitting in the chamber.
Details of the human exposure facility 
have been described previously (Brook et al. 
2002; Petrovic et al. 2000; Urch et al. 2005). 
Briefly, ambient particles with aerodynamic 
diameter < 2.5 µm were drawn through an 
inlet outside of the laboratory, concentrated 
using a Harvard virtual impactor (Sioutas et al. 
1995), diluted to the target concentration, and 
delivered via facemask to subjects seated at rest 
inside an enclosure (Petrovic et al. 2000). The 
achieved CAPs mass concentration was meas-
ured gravimetrically from samples obtained 
via a port proximal to the facemask (Petrovic 
et al. 2000). The concentrator was run during 
the non-CAPs exposures, but particles were 
removed with a HEPA filter proximal to the 
facemask (Petrovic et al. 2000; Urch et al. 
2004). O3 was produced with an arc genera-
tor using medical-grade oxygen and delivered 
upstream of the particle concentrator. O3 con-
centration was maintained at approximately 
120 ppb measured just upstream of the face-
mask by an O3 analyzer (model 1008-RS; 
Dasibi Environmental, Glendale, CA, USA). 
Ambient temperature, relative humidity, and 
ambient gaseous pollutant concentrations 
including carbon monoxide, carbon dioxide, 
sulfur dioxide, nitrogen oxide, and nitrogen 
dioxide were monitored during the exposure 
as previously described (Petrovic et al. 2000; 
Urch et al. 2004). In addition, CAPs mass con-
centration was continuously monitored using 
a tapered element oscillating microbalance 
moni  tor (TEOM) (model 1400a; Rupprecht 
& Patashnick Co. Inc., Albany, NY, USA).
Outcome measurement. The primary out-
come measure was change in several HRV 
indices between the start and end of each 2-hr 
exposure (Figure 1). Electrocardiograms were 
continuously recorded using digital Holter 
monitors (Marquette Medical Systems, 
Milwaukee, WI, USA) and subsequently 
stored and analyzed on a Marquette Medical 
Systems (MARS) Unity workstation. Beat 
annotations were automatically assigned by 
the software and reviewed by an investigator 
blinded to the exposure status. 
Calculations for time domain [standard 
deviation of NN intervals (SDNN); square 
root of the mean squared differences of suc-
cessive NN intervals (rMSSD); proportion 
of successive NN intervals with differences 
> 50 msec (pNN50)] and frequency domain 
[low-frequency (LF) power (0.04‒0.15 Hz), 
high-frequency (HF) power (0.04‒0.15 Hz), 
and their ratio (LF/HF)] HRV parameters 
were evaluated on 5-min intervals of ECG 
data using standard techniques (Task Force 
of the European Society of Cardiology 1996). 
Only normal sinus beats were used. These 
measures were calculated at 0, 30, 60, 90, and 
120 min into the exposure (Figure 1). For 
intervals with < 90% valid quality recording, 
the previous 5-min window was used instead. 
In addition, systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) were 
Figure 1. Timeline of BP and HRV measures.
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Table 1. Baseline subject characteristics and exposure data.
Characteristic  Overall  Study A  Study B
No. of subjects  50a  21  30
Age [years, mean ± SD (range)]  27.08 ± 7.13 (19–48)  27.29 ± 5.60  26.93 ± 8.13
Male [no. (%)]  24 (47)  9 (43)  15 (50)
Ethnicity [no. (%)]     
  White   24 (49)  10 (48)  14 (50)
  Black   7 (7)  4 (19)  3 (11)
  Asian   16 (33)  6 (29)  10 (36)
  Other  2 (4)  1 (5)  1 (4)
Body mass index [kg/m2 (mean ± SD)]  22.72 ± 3.24  22.35 ± 2.47  23.22 ± 3.54
Medical history    10 Asthmatics  None
CAPs [µg/m3 (mean ± SD)]  127.03 ± 62.13  101.16 ± 42.43  146.20 ± 67.58
O3 [ppb (mean ± SD)]  113.86 ± 6.62  118.69 ± 3.31  110.30 ± 6.19
aOne subject was included in both studies.
Figure 2. Percentage distribution of CAPs exposure concentrations. The line indicates the fitted normal 
density curve.
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Figure 3. Change in SDNN by exposure from baseline over 2 hr. Error bars indicate SE.
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measured every 30 min throughout the 2-hr 
exposure (Figure 1) using a calibrated and 
automated sphygmomanometer (Oscar-1 or 
Oscar-2; SunTech Medical Instruments, Inc., 
Raleigh, NC, USA). Where the data were 
available, the analysis used a mean of three 
successive BP measurements at each time 
point. We also included mean arterial pres-
sure (MAP) in our measurements, defined as 
the weighted average (2:1) of DBP and SBP. 
Furthermore, minute ventilation and respira-
tory frequency were recorded every 30 min 
during the exposure using a turbine-type flow 
transducer (VMM401; Interface Associates, 
Aliso Viejo, CA, USA).
Statistical analysis. We used linear mixed-
effects models to evaluate the effects of expo-
sure while accounting for the correlation 
between multiple measurements within each 
individual. In a first analysis, models included 
fixed effects for exposure (in four categories: 
FA, CAPs, O3, and CAPs + O3), age (linear 
continuous), sex, and asthmatic status (yes/
no), and a random-subject intercept, model-
ing the primary outcome of change in HRV 
or BP between start and end of exposure 
as linear continuous variables. In a second 
analysis, we entered average measured CAPs 
mass concentration into the model as a linear 
continuous-exposure variable and stratified 
the CAPs dose‒response analysis by presence 
or absence of O3. 
We conducted several sensitivity analyses 
to evaluate the robustness of our main results. 
First, to assess whether additional time points 
of HRV and BP data would improve the reso-
lution of the models, we modeled the mean 
change in outcome across five measurements 
taken every 30 min during the 2-hr exposure. 
Second, we evaluated whether the responses to 
CAPs and O3 differed in asthmatics versus non-
asthmatics by adding exposure-by-asthmatic 
status interactions to the main model. Third, 
we controlled for potential confounding by 
minute ventilation and respiratory frequency, 
which can especially affect HF HRV (Hayano 
et al. 1991; Task Force of the European Society 
of Cardiology 1996). Fourth, we added average 
heart rate from the prior 5-min interval as a 
fixed effect.
All hypothesis tests were two-sided, and 
p < 0.05 was considered statistically signifi-
cant. We used the SAS statistical analysis 
package (version 9.1; SAS Institute, Cary, 
NC, USA) for all analyses. Regression diag-
nostics were performed to verify model 
assumptions. 
Results
Subject characteristics and exposures. A total 
of 50 subjects with complete Holter data were 
included from both studies in the analyses 
(Table 1). The main distinction between 
study A and study B was the inclusion of 
10 mildly asthmatic subjects in study A. The 
number of exposures with complete Holter 
data in each exposure category was as follows: 
53 exposures to CAPs; 53 exposures to CAPs 
+ O3; 40 exposures to O3; and 42 exposures 
to FA (sham). By design, a subset of partici-
pants in study A underwent additional expo-
sures to CAPs at a lower target concentration, 
resulting in relatively fewer FA- and O3-only 
exposures. The mean CAPs mass concentra-
tion was 121.6 ± 48.0 µg/m3 (Figure 2). The 
mean O3 concentration was 113.9 ± 6.6 ppb. 
During FA exposure, the mean CAPs mass 
and O3 concentrations were 2.3 ± 5.7 µg/m3 
and 10.0 ± 7.4 ppb, respectively.
Outcomes. Heart rate variability. As illus-
trated in Figure 3, for all of the exposures, 
subjects had a net increase in SDNN as the 
2-hr exposure progressed. The trend with time 
was similar for the other indices of HRV. 
The primary analysis, change in HRV indices 
between the start and end of the 2-hr expo-
sure period, yielded no consistent differences 
between the exposure categories (Table 2). 
HF HRV showed a statistically significant 
increase for the CAPs-only exposure (p = 
0.046) and a similar trend for O3 exposure 
(p = 0.051) when compared with filtered air. 
Sensitivity analyses separately incorporating 
minute ventilation, respiratory frequency, 
average heart rate, or the asthma interaction 
term into the main model abolished this dif-
ference and did not materially alter findings 
for the other HRV outcomes. Analyses using 
the mean of all five HRV measurements dur-
ing the 2-hr exposure or assessing change in 
HRV by minutes into exposure did not mate-
rially alter our conclusions. We did not find 
evidence of heterogeneity by asthmatic status.
We also analyzed the dose–response 
relationship between CAPs mass concentra-
tion and change in the HRV indices, strati-
fied by presence or absence of O3. For those 
exposures without O3 (i.e., CAPs alone and 
FA), there was no significant dose‒response 
relationship between gravimetric CAPs mass 
concentration and any measure of HRV. 
However, when analyzing the CAPs mass 
concentration relationship for exposures with 
O3 (i.e., CAPs + O3 and O3 alone), there was 
a suggestion of negative dose‒response slopes 
(Table 3) between CAPs mass concentration 
and several HRV indices. This trend was seen 
in SDNN, rMSSD, and HF and was statisti-
cally significant for LF (p = 0.02). 
Table 2. Change in HRV (± SE) between start and 
end of 2-hr exposure period.
HRV variable/  ΔPre- and 
Exposure   postexposure  p-Valuea
Δ5-Min average heart rate (bpm)
  FA  2.57 ± 0.91 
  CAPs  2.09 ± 0.93  0.61
 O 3  1.55 ± 0.95  0.28
  CAPs + O3  2.04 ± 1.09  0.62
ΔSDNN (msec)  
  FA  22.14 ± 4.87 
  CAPs  26.31 ± 5.10  0.41
 O 3  34.29 ± 7.30  0.098
  CAPs + O3  17.74 ± 4.29  0.31
ΔrMSSD (msec)  
  FA  –4.70 ± 6.28 
  CAPs  5.51 ± 7.74  0.19
  O3  16.77 ± 11.92  0.07
  CAPs + O3  –0.12 ± 6.79  0.50
ΔpNN50 (%)   
  FA  –1.48 ± 2.01 
  CAPs  0.25 ± 1.74  0.32
 O 3  1.28 ± 2.32  0.24
  CAPs + O3  –1.18 ± 2.33  0.90
ΔLF (msec2)   
  FA  456 ± 449 
  CAPs  1381 ± 671  0.17
 O 3  1915 ± 1167  0.21
  CAPs + O3  482 ± 474  0.96
ΔHF (msec2)   
  FA  –149 ± 198  
  CAPs  348 ± 247  0.046
 O 3  467 ± 312  0.051
  CAPs + O3  21 ± 239  0.48
ΔLF/HF ratio   
  FA  0.73 ± 0.45 
  CAPs  0.62 ± 0.55  0.84
 O 3  0.52 ± 0.56  0.70
  CAPs + O3  0.12 ± 0.62  0.33
aCompared with exposure to filtered air.
Table 3. Dose–response slope for CAPs mass concentration versus 2-hr change in HRV.
HRV measure  Exposure  Slopea  SE  p-Valueb   p-Contrastc
Δ5-min   No O3  –0.033  0.060  0.58
  average heart rate (bpm)  With O3  0.014  0.057  0.80  0.56
ΔSDNN (msec)  No O3  –0.0033  0.39  0.99
  With O3  –0.84  0.37  0.03  0.12
ΔrMSSD (msec)  No O3  0.38  0.59  0.52
  With O3  –0.96  0.56  0.09  0.10
ΔpNN50 (%)  No O3  0.08  0.13  0.53
  With O3  –0.13  0.12  0.28  0.23
ΔLF (msec2)  No O3  80.38  55.71  0.15
  With O3  –94.51  52.53  0.074  0.02
ΔHF (msec2)  No O3  18.97  17.57  0.28
  With O3  –22.19  16.63  0.18  0.09
ΔLF/HF ratio  No O3  0.0048  0.034  0.89
  With O3  –0.034  0.032  0.29  0.41
aSlopes reported for a 10-µg/m3 change in CAPs mass concentration. bp-Homogeneity. cp-Contrast between slope with O3 
and slope without O3.Fakhri et al.
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Blood pressure. A statistically significant 
increase in DBP for CAPs + O3 relative to 
FA was previously reported for the subjects in 
study B (Urch et al. 2005). Therefore, in the 
current analysis, we focused only on the BP 
data from study A. 
We assessed the change in BP between 
the start and end of the the 2-hr exposure 
(Table 4) as well as the change in BP at each 
30-min interval. Similar to data from study B, 
subjects in study A demonstrated a statistically 
significant increase in DBP (1.97 mmHg, p = 
0.02) in response to CAPs + O3. Figure 4 
shows DBP at 30-min intervals throughout 
the exposure period. All the subjects experi-
enced an equilibration period after entering 
the chamber when their DBP decreased ini-
tially with time. After this equilibration, the 
CAPs + O3 exposure began to diverge from 
the other exposures, demonstrating a statisti-
cally significant increase relative to filtered 
air at 60 min (p < 0.03). No clear pattern 
emerged among the exposures for SBP and 
MAP, although SBP tended to decrease in the 
O3-only exposure (Table 4).
Sensitivity analyses additionally controlling 
for minute ventilation, respiratory frequency, 
or heart rate did not materially alter the results. 
We did not find evidence of heterogeneity of 
effect by asthmatic status.
Discussion
To our knowledge, this is the largest study 
assessing the acute impact of CAPs exposure 
on HRV in young healthy adults. In addi-
tion, with recent evidence in animals showing 
effects of combined O3 and particulate expo-
sure on HRV (Hamade et al. 2008), this is also 
the largest human controlled-exposure study 
looking at the impact of combined exposure 
to CAPs and O3 on HRV.
In this study, HRV indices were used as 
surrogate markers of autonomic tone (Task 
Force of the European Society of Cardiology 
1996). The time-domain measures rMSSD 
and pNN50 are thought to reflect para-
sympathetic influences, whereas SDNN may 
also have sympathetic influence (Dekker et al. 
2000; Hayano et al. 1991; Task Force of 
the European Society of Cardiology 1996). 
Among the frequency-domain parameters, 
HF almost exclusively reflects parasympathetic 
influence and respiratory variation (Hayano 
et al. 1991; Task Force of the European 
Society of Cardiology 1996). Interpreting 
changes in LF and LF/HF is controversial; 
LF may to some extent reflect sympathetic 
influences, whereas LF/HF possibly reflects 
sympathovagal balance (Task Force of the 
European Society of Cardiology 1996). 
There is a large body of evidence suggest-
ing that cardiovascular response to pollut-
ants varies with age and comorbidities (Brook 
et al. 2004; Dockery et al. 1993; Goldberg 
et al. 2001; Katsouyanni et al. 2001). In this 
group of young healthy adult subjects, we did 
not detect a consistent pattern for changes in 
HRV indices among the exposure categories. 
HF had a statistically significant difference 
in some of the exposures relative to filtered 
air. However, given that HF is particularly 
sensitive to respiratory variation (Task Force 
of the European Society of Cardiology 1996), 
adjusting for respiratory parameters abolished 
this difference. Despite the absence of a clear 
pattern of difference in the categorical expo-
sure models, the dose–response analysis in 
the setting of concomitant O3 demonstrated 
a trend toward negative linear association 
between CAPs mass concentration and change 
in several HRV indices, with a statistically 
significant relationship for LF HRV. No 
such relationship existed without O3 pres-
ent. Our findings for CAPs alone agree with 
findings in other studies reporting the lack 
of significant effect of CAPs alone on HRV 
in young healthy subjects, despite significant 
effects noted in elderly subjects (Devlin et al. 
2003; Gong et al. 2003). The suggestion of 
dose–response CAPs effects in the presence 
of O3 is of import, given emerging research 
priorities emphasizing studies of copollutants 
and dose–response relationships (National 
Research Council 2004). 
Our results corroborate previous findings of 
increase in DBP with CAPs + O3 (Urch et al. 
2005). The effect became statistically signifi-
cant at 60 min and became more pronounced 
toward the end of the exposure. With regard 
to SBP, only one human controlled-exposure 
study (Gong et al. 2003) has demonstrated 
modest changes with CAPs exposure, whereas 
other studies have not shown effects (Devlin 
et al. 2003; Urch et al. 2005). In one exposure 
study conducted in canines exposed to CAPs, 
the increase in DBP was of greater magnitude 
than the increase in SBP (Bartoli et al. 2009). 
One possible explanation for the apparent 
disparity between SBP and DBP change in 
our study is the attenuation of peripheral SBP 
amplification in young adults (Franklin et al. 
2005). It has been shown in adults < 50 years 
of age that for a given increase in central and 
peripheral DBP, peripherally measured SBP 
does not increase in parallel as it does for older 
adults (Wilkinson et al. 2001). Alternatively, 
the baseline increase in SBP in our filtered-air 
control group and the greater variation and 
lability of SBP measurements relative to DBP 
in our study may have made it more difficult 
to appreciate a meaningfully different change 
in SBP.
The effects of CAPs + O3 on BP, and pos-
sibly in a dose–response fashion on HRV, 
raise important questions about the interac-
tion and possible synergy between the two 
components in their impact on cardiovascular 
physiology. With regard to possible mecha-
nisms for pollutant-mediated changes in sys-
temic physiology, it has been demonstrated in 
animal models that O3 exposure leads to lung 
hyperpermeability (Kleeberger et al. 2000), 
possibly increasing systemic toxin absorption 
Figure 4. Change in DBP over 2 hr by exposure. Error bars indicate SE.
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Table 4. Change in BP between exposure start and 
exposure end. 
BP measure/exposure  ΔBP ± SE  p-Valuea
ΔSBP (mmHg)
  FA  2.32 ± 1.79 
  CAPs  0.04 ± 2.51  0.37
 O 3  –1.18 ± 1.96  0.07
  CAPs + O3  0.90 ± 2.00  0.48
ΔDBP (mmHg)
  FA  –0.84 ± 1.20 
  CAPs  –0.87 ± 1.43  0.98
 O 3  –0.23 ± 1.57  0.70
  CAPs + O3  1.97 ± 1.21  0.02
ΔMAP
  FA  0.17 ± 1.21 
  CAPs  –0.62 ± 1.65  0.63
 O 3  –0.56 ± 1.48  0.62
  CAPs + O3  1.64 ± 1.15  0.20
aCompared with exposure to filtered air.HRV and blood pressure response to CAPs and ozone
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or increasing local inflammation. Other 
  possibilities include O3-mediated free radical 
production or conversion of particles to com-
pounds with greater tendency to deposit on 
surfaces, the latter having been demonstrated 
with ammonium nitrate particles (Meng et al. 
1997). In humans, generated ammonium 
nitrate particle with O3 combination exposure 
has recently been shown to suppress HRV 
(Power et al. 2008). The changes in DBP may 
be related to changes in autonomic tone, as 
shown in cohort studies demonstrating cor-
relation among HRV measures and incident 
hypertension (Singh et al. 1998), but the data 
in our study do not consistently validate this 
hypothesis. Alternatively, the DBP response 
may be related to direct vasoconstriction 
(Brook et al. 2002; Urch et al. 2004, 2005) or 
increased peripheral vascular resistance inde-
pendent of autonomic changes, but we did 
not directly test this hypothesis in this study. 
Our study has several potential limitations 
that need to be considered. First, we could not 
control for ambient pollutant exposure prior 
to each visit. Future studies may address this 
limitation with personal monitoring, detailed 
time–activity diaries, or optimally, having 
study participants sleep onsite the night pre-
ceding any experiments. Second, because the 
study was designed to examine acute effects, 
we could not assess more prolonged time-
dependent effects of exposures (McDonnell 
et al. 2007) or effects resulting from sequen-
tial rather than concomitant exposures. Future 
studies may address this limitation using stag-
gered and/or prolonged exposures. Third, 
because our particle concentrator does not 
concentrate particles < 0.1 µm, limiting parti-
cle size to predominantly accumulation mode, 
we could not assess the role of ultrafine par-
ticles. Controlled-exposure studies comparing 
the toxicity of ultrafine, fine, and coarse par-
ticles in humans are clearly needed. Fourth, 
we did not measure or remove volatile organic 
compounds, which likely have independent 
effects (Bhatnagar 2006). However, the cross-
over design of this study reduced potential 
confounding either by exposure variation or 
by other unmeasured confounders. 
An important strength of this study is that 
CAPs exposures were derived from real-world 
ambient particles from an urban environment. 
According to one sampling campaign in 1997 
through 1999, PM2.5 in Toronto typically 
includes approximately one-quarter organic 
carbon, similar portions sulfates, nitrates, 
ammonium, and black carbon, and small por-
tions of soil or other constituents (Bhatnagar 
2006). The large sample size of our study and 
the fact that composition of CAPs changes 
daily in these experiments can be exploited 
in future analyses to identify components or 
constituents of CAPs that may be associated 
with greater effects.
Conclusion
In summary, ambient PM2.5 has been shown 
to impact HRV in epidemiologic studies of 
populations considered vulnerable on the 
basis of age or chronic diseases (Creason et al. 
2001; Gold et al. 2000; Liao et al. 1999; 
Magari et al. 2001; Pope et al. 1999).Whereas 
most epidemiologic studies focus on effects 
ranging from several hours to days (Creason 
et al. 2001; Liao et al. 1999; Magari et al. 
2001; Pope et al. 1999), we attempted to 
study acute effects within the span of 2 hr. 
Our data suggest that in younger subjects, 
CAPs alone does not produce significant 
effects, but when combined with O3, there 
is an increase in DBP that may be mediated 
through autonomic changes. The possibil-
ity of an autonomic effect is suggested in the 
dose–response relationship of HRV to CAPs 
mass concentration, although this is of small 
magnitude and borderline statistical signifi-
cance in this group of young healthy adult 
subjects. Given that CAPs alone produce 
HRV changes in more vulnerable populations 
(Creason et al. 2001; Devlin et al. 2003; Gold 
et al. 2000; Liao et al. 1999; Magari et al. 
2001; Pope et al. 1999), elderly subjects or 
subjects with comorbidities may experience 
even stronger synergistic effects with simulta-
neous controlled exposure to CAPs and O3.
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